AR056460A1 - ANTAGONISTAS DE CGRP SELECCIONADOS, PROCEDIMIENTOS PARA SU PREPARACIoN, ASI COMO SU USO COMO MEDICAMENTOS - Google Patents

ANTAGONISTAS DE CGRP SELECCIONADOS, PROCEDIMIENTOS PARA SU PREPARACIoN, ASI COMO SU USO COMO MEDICAMENTOS

Info

Publication number
AR056460A1
AR056460A1 ARP060103563A ARP060103563A AR056460A1 AR 056460 A1 AR056460 A1 AR 056460A1 AR P060103563 A ARP060103563 A AR P060103563A AR P060103563 A ARP060103563 A AR P060103563A AR 056460 A1 AR056460 A1 AR 056460A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
group
formulas
salts
Prior art date
Application number
ARP060103563A
Other languages
English (en)
Inventor
Hubert Mueller
Klaus Rudolf
Philipp Lustenberger
Gerhard Schaenzle
Marco Santagostino
Dirk Stenkamp
Kirsten Arndt
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR056460A1 publication Critical patent/AR056460A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)

Abstract

Sus tautomeros, sus isomeros, sus diastereoisomeros, sus enantiomeros, sus hidratos, sus mezclas y sus sales, así como los hidratos de las sales, en especial sus sales fisiologicamente tolerables con ácidos o bases inorgánicos u orgánicos, así como aquellos compuestos de la formula general I, en los que uno o varios átomos de hidrogeno se intercambiaron por deuterio, medicamentos que contienen estos compuestos, su uso y procedimientos para su preparacion. REIVINDICACION 1.- Antagonistas de CGRP de la formula general I (I) en la que R1 significa un resto seleccionado del grupo de formulas (2) en los que R1.1. representa H o H3C-O-, R2 significa un resto seleccionado del grupo de formulas (3) R3 un grupo de la formula general (4) en los que X N o C, R3.1. representa H, alquilo C1-3- o R3.1.1.-(O)C-, R3.1.1. H, alquilo C1-6, H2N-alquileno C2-4, (alquil C1-3)-NH-alquileno C2-4, (alquil C1-3)2N-alquileno C2-4, H2N-C(O)-alquileno C1-3, (alquil C1-3)-NH-C(O)-alquileno C1-3, (alquil C1- 3)2N-C(O)-alquileno C1-3 o R3.1.1.1-alquileno C2-4, R3.1.1.1 un resto seleccionado del grupo de formulas (5) R3.2 un par de electrones libres cuando X = N, o R3.2 H, alquilo C1-3 o R3.2.1-O-C(O)-, cuando X = N, o R3.2 H, alquilo C1-3 o R3.2.1-O-C(O)- , cuando X = C, R3.2.1 H, alquilo C1-6, H2N-alquileno C2-4, (alquil C1-3)-NH-alquileno C2-4, (alquil C1-3)2N-alquileno C2-4, H2N-C(O)-alquileno C1-3, (alquil C1-3)-NH-C(O)-alquileno C1-3, (alquil C1-3)2N-C(O)-alquileno C1-3 o R3.2.1.1-alquileno C2- 4, R3.2.1.1 un resto seleccionado del grupo de formulas (5) R4 un grupo de formulas generales (6) en los que Y C y R4.1 H o alquilo C1-3-, o Y N y R4.1 representa un par de electrones libres, con la condicion de que X e Y no sean al mismo tiempo N, R4.2 H, alquilo C1-3- o R4.2.1-(O)C-, R4.2.1 H, alquilo C1-6, H2N-alquileno C2-4 (alquil C1-3)-NH-alquileno C2-4, (alquil C1-3)2N-alquileno C2-4, H2N-C(O)-alquileno C1-3 (alquil C1-3-NH-C(O)-alquileno C1-3, (alquil C1-3)2N-C(O)-alquileno C1-3 o R4.2.1.1-alquileno C2-4, R4.2.1.1 un resto seleccionado del grupo de formulas (5) y R4.3 H, alquilo C1-6-, H2N-alquileno C2-4-, (alquil C1-3)-NH- alquileno C2-4-, (alquil C1-3)2N-alquileno C2-4-, H2N-C(O)-alquileno C1-3-, (alquil C1-3)-NH-C(O)- alquileno C1-3-, (alquil C1-3)2N-C(O)-alquileno C1-3- o R4.3.1-alquileno C2-4- y R4.3.1 un resto seleccionado del grupo de formulas (5) R5.1 H, alquilo C1-3, R5.1.1-O-C(O)-, R5.1.1-O-C(O)-alquilen C1-3-NH-, R5.1.1-O-C-(O)-alquilen C1-3-N(alquilo C1- 3), R5.1.1-O-C(O)-alquilen C1-3-O-, R5.1.1-O-C(O)-alquileno C1-3, R5.1.1-O-C(O)-C(O)-, R5.1.1-O-C(O)-C(O)-O-, R5.1.1-O-C(O)-alquilen C1-3-C(O)- o R5.1.1-O-C(O)-alquilen C1-3-C(O)-O-, R5.1.1 H, alquilo C1-8-, fenilo- indanilo-, piridil-alquileno C1-3- , HO-alquileno C2-4-, alquil C1-6-O-alquileno C2-4-, H2N-alquileno C2-4-, (alquil C1-6)-NH- alquileno C2-4-, (alquil C1-6)2N-alquileno C2-4-, H2N-C(O)-alquileno C1-3-, (alquil C1-6)-NH-C(O)-alquileno C1-3-, (alquil C1-6)2N-C(O)-alquileno C1-3-, alquil C1-6-C(O)-O-alquileno C1-3-, alquil C1-6-O-C(O)-O-alquileno C1-3-, R5.1.1.1-C(O)-alquileno C1-3- o R5.1.1.2-alquileno C2-4-, R5.1.1.1 un resto seleccionado del grupo de formulas (7) R5.1.1.2 un resto seleccionado del grupo de formulas (5) R5.2 h, alquilo C1-3-, R5.2.1-O-C(O)-alquilen C1-3-NH-, R5.2.1-O-C-(O)alquilen C1-3-O-, R5.2.1-O-C(O)-alquileno C1-3-, R5.2.1-O-C(O)-C(O)- o R5.2.1-O-C(O)-alquilen C1-3-C(O)-, R5.2.1 H alquilo C1-8, fenilo, indanilo-, piridil-alquileno C1-3-, HO- alquileno C2-4-, alquil C1-6-O-alquileno C2-4-, alquil C1-6-O-alquilen C2-4-O-alquileno C2-4-, H2N-alquileno C2-4-, (alquil C1-6)-NH-alquileno C2-4-, (alquil C1-6)-NH-alquileno C2-4-, (alquil C1-6)2N-alquileno C2-4-, H2N-C(O)-alquileno C1-3-, (alquil C1-6)-NH-C(O)-alquileno C1-3-, (alquil C1-6)2N-C(O)-alquileno C1-3-, alquil C1-6-C(O)-O-alquileno C1-3-, alquil C1-6-O-C(O)-O-alquileno C1-3-, R5.2.1.1-C(O)-alquileno C1-3- o R5.2.1.2-alquileno C2-4-, R5.2.1.1 un resto seleccionado del grupo de formulas (7) y R5.2.1.2 un resto seleccionado del grupo de formulas (5), o R5.2.1 un grupo de la formula (8) con la condicion de que al menos uno de los radicales R3.1, R3.2, R4.2, R5.1 o R5.2 sea otro radical distinto de H o alquilo C1-3-, sus tautomeros, sus diastereoisomeros, sus enantiomeros, sus hidratos, sus mezclas y sus sales, así como los hidratos de las sales, en particular sus sales fisiologicamente compatibles con ácidos o bases inorgánicos u orgánicos.
ARP060103563A 2005-08-17 2006-08-16 ANTAGONISTAS DE CGRP SELECCIONADOS, PROCEDIMIENTOS PARA SU PREPARACIoN, ASI COMO SU USO COMO MEDICAMENTOS AR056460A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005038831A DE102005038831A1 (de) 2005-08-17 2005-08-17 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005050953A DE102005050953A1 (de) 2005-08-17 2005-10-25 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR056460A1 true AR056460A1 (es) 2007-10-10

Family

ID=37496772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103563A AR056460A1 (es) 2005-08-17 2006-08-16 ANTAGONISTAS DE CGRP SELECCIONADOS, PROCEDIMIENTOS PARA SU PREPARACIoN, ASI COMO SU USO COMO MEDICAMENTOS

Country Status (18)

Country Link
US (3) US7579341B2 (es)
EP (1) EP1917256A2 (es)
JP (2) JP4852607B2 (es)
KR (1) KR20080039990A (es)
AR (1) AR056460A1 (es)
AU (1) AU2006281416A1 (es)
BR (1) BRPI0614831A2 (es)
CA (1) CA2618834A1 (es)
DE (2) DE102005038831A1 (es)
EA (1) EA200800439A1 (es)
EC (1) ECSP088194A (es)
IL (1) IL189497A0 (es)
MX (1) MX2008001977A (es)
NO (1) NO20076680L (es)
PE (2) PE20070355A1 (es)
TW (1) TW200740795A (es)
UY (1) UY29749A1 (es)
WO (1) WO2007020261A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU2007255395A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with CGRP-antagonists
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
JP2010540494A (ja) 2007-09-28 2010-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
USD922701S1 (en) 2019-12-23 2021-06-15 Samsung Electronics Co., Ltd. Shoe care machine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ82399A3 (cs) 1996-09-10 1999-06-16 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050282857A1 (en) 2004-04-15 2005-12-22 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018796A1 (de) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004044145B3 (de) * 2004-09-13 2006-04-13 Robert Bosch Gmbh Reflektormodul für einen photometrischen Gassensor
DE102004063752A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063753A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PE20070355A1 (es) 2007-04-30
EP1917256A2 (de) 2008-05-07
US20070049581A1 (en) 2007-03-01
DE102005038831A1 (de) 2007-02-22
EA200800439A1 (ru) 2008-08-29
UY29749A1 (es) 2007-03-30
KR20080039990A (ko) 2008-05-07
JP2009505985A (ja) 2009-02-12
PE20100570A1 (es) 2010-08-16
JP4852607B2 (ja) 2012-01-11
TW200740795A (en) 2007-11-01
DE102005050953A1 (de) 2007-04-26
US20110034444A1 (en) 2011-02-10
US20100004228A1 (en) 2010-01-07
BRPI0614831A2 (pt) 2009-05-19
US7579341B2 (en) 2009-08-25
AU2006281416A1 (en) 2007-02-22
WO2007020261A3 (de) 2008-08-21
CA2618834A1 (en) 2007-02-22
NO20076680L (no) 2008-04-30
ECSP088194A (es) 2008-03-26
MX2008001977A (es) 2008-03-25
WO2007020261A2 (de) 2007-02-22
IL189497A0 (en) 2008-08-07
JP2011256200A (ja) 2011-12-22
US7858622B2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
AR056460A1 (es) ANTAGONISTAS DE CGRP SELECCIONADOS, PROCEDIMIENTOS PARA SU PREPARACIoN, ASI COMO SU USO COMO MEDICAMENTOS
AR056205A1 (es) Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, metodo de preparacion y usos para el tratamiento agudo y preventivo de dolores de cabeza, en particular migranas, y otras enfermedades
UY29437A1 (es) Nuevos antagonistas de cgrp
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
AR068912A1 (es) Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR066770A1 (es) Derivados de piridazinona
ES2436020T3 (es) Derivados de sulfonamida sustituidos
AR055635A1 (es) Uso de sulfonanilidas como herbicidas
AR246101A1 (es) Una composicion organopolisiloxano.
PE20050652A1 (es) Mezclas que contienen estrobilurinas y moduladores de etileno
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR062426A1 (es) Compuestos heterociclicos utiles para preparar medicamentos usados en la terapia del dolor.
AR066769A1 (es) Derivados de arileter-piridazinona
AR054583A1 (es) Pantoprazol isotopicamente sustituido
GT200300010A (es) Esteres hidroxamato del acido n-(4-fenil sustituido)-antranilico
ECSP10010105A (es) Antagonistas de cgrp
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
AR044342A1 (es) Derivados de bencimidazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure